bioRxivCancer BiologyPreprint
The CTCF Paralog BORIS Contributes to the Ovarian Cancer Transcriptional Program by Relaxing CTCF-mediated 3D Genome Organization
Dharmendra Nath BhattiD, Arielle ScottiD, Ludmila Krymskaya, Tovah E. MarkowitziD, Emma PriceiD, Yon Ju JiiD, Dmitri I. LoukinoviD, Maria K. TraveriD, Joseph A. BrzostowskiiD, Victor V. LobanenkoviD, Elena M. PugachevaiD
Abstract
Disruption of three-dimensional genome architecture is a major driver of cancer initiation and progression, frequently arising from genetic and epigenetic alterations at CTCF- and cohesin-bound chromatin anchors. These same chromatin loop anchors can also be occupied by the germ cell-specific CTCF paralog CTCFL (BORIS), which is aberrantly activated in multiple malignancies. Here, we show that in ovarian cancer cells, BORIS activation establishes a distinct transcriptional program that collapses following loss of BORIS chromatin binding and is accompanied by widespread changes in CTCF and cohesin occupancy, histone modifications, and chromatin accessibility. These BORIS-dependent transcriptional alterations occur in long-range genomic clusters, resulting in the coordinated activation or repression of neighboring genes, including hormonally regulated gene families. BORIS loss also increases topologically associating domain (TAD) insulation, strengthens A/B compartment segregation and chromatin loop interactions, and results in a more compact and constrained chromatin architecture. Together, our findings suggest that aberrant BORIS activation promotes transcriptional reprogramming by weakening CTCF-mediated chromatin insulation and relaxing three-dimensional genome organization in ovarian cancer. SignificanceHigh-grade serous ovarian carcinoma, the most common subtype of ovarian cancer, remains one of the deadliest gynecological malignancies because of its late diagnosis, extensive genomic instability, and frequent therapeutic resistance. The lack of reliable biomarkers for early detection underscores the need to identify new molecular drivers of disease initiation and progression. Here, we show that the germline-specific gene CTCFL (BORIS) is aberrantly activated in high-grade serous ovarian carcinoma, where it remodels transcriptional, epigenetic, and three-dimensional genome organization by occupying CTCF-bound chromatin loop anchors and weakening CTCF-mediated chromatin insulation. These findings identify BORIS as a key regulator of transcriptional reprogramming in ovarian cancer and support its further investigation as both a prognostic biomarker and a potential therapeutic target.
- organism: human
- assay: bulk RNA-seq
- assay: ChIP-seq
- assay: DNA methylation
- assay: Hi-C
- research focus: chromatin & epigenetic regulation
- research focus: cancer & tumor microenvironment
- research focus: gene regulatory network inference
- approach: experimental assay
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cancer-specific CTCF binding facilitates oncogenic transcriptional dysregulation
Celestia Fang, Zhenjia Wang, … Chongzhi Zang·Genome biologyPeer-reviewed·Sep 15, 2020
- Rewiring of master transcription factor cistromes during high-grade serous ovarian cancer development
R. Nameki, H. Chang, … K. Lawrenson·bioRxiv·Apr 11, 2023
- BORIS/CTCFL-mediated chromatin accessibility alterations promote a pro-invasive transcriptional signature in melanoma cells
R. Moscona, S. Janssen, … E. Rubin·bioRxiv·Feb 11, 2022
- Activation of the Androgen Receptor gene by BORIS/CTCFL in prostate cancer cells
Yukti Hari-Gupta, Georgia-Xanthi Kita, … Elena Klenova·bioRxiv·Sep 29, 2017
- Incomplete developmental silencing of cancer-testis antigen BORIS in humanized mouse model promotes cancer susceptibility
Emma Price, Elena M. Pugacheva, … Victor V. Lobanenkov·bioRxiv·Dec 26, 2025
- TP53 loss initiates chromosomal instability in high-grade serous ovarian cancer
D. Bronder, D. Wangsa, … S. S. Taylor·bioRxiv·Mar 12, 2021